Effect of 5-HT\textsubscript{7} receptor blockade on liver regeneration after 60-70\% partial hepatectomy

Konstantinos N Tzirogiannis\textsuperscript{1,1}, Kalliopi T Kourentzi\textsuperscript{1,†}, Sofia Zyga\textsuperscript{2}, Vassiliki Papalimneou\textsuperscript{3}, Maria Tsironi\textsuperscript{2}, Agni D Grypioti\textsuperscript{1}, Ioannis Protopsaltis\textsuperscript{4}, Dimitrios Panidis\textsuperscript{2} and Georgios I Panoutsopoulos\textsuperscript{5,*}

Abstract

Background: Serotonin exhibits a vast repertoire of actions including cell proliferation and differentiation. The effect of serotonin, as an incomplete mitogen, on liver regeneration has recently been unveiled and is mediated through 5-HT\textsubscript{2} receptor. The aim of the present study was to investigate the effect of 5-HT\textsubscript{7} receptor blockade on liver regeneration after partial hepatectomy.

Methods: Male Wistar rats were subjected to 60-70\% partial hepatectomy. 5-HT\textsubscript{7} receptor blockade was applied by intraperitoneal administration of SB-269970 hydrochloride two hours prior to and sixteen hours after partial hepatectomy and by intraperitoneal administration of SB-258719 sixteen hours after partial hepatectomy. Animals were sacrificed at different time points until 72 h after partial hepatectomy. Liver regeneration was evaluated by \textsuperscript{[3]}H-thymidine incorporation into hepatic DNA, the mitotic index in hematoxylin-eosin (HE) sections and by immunochemical detection of Ki67 nuclear antigen. Reversion of 5-HT\textsubscript{7} blockade was performed by intraperitoneal administration of AS-19. Serum and liver tissue lipids were also quantified.

Results: Liver regeneration peaked at 24 h (\textsuperscript{[3]}H-thymidine incorporation into hepatic DNA and mitotic index by immunochemical detection of Ki67) and at 32 h (mitotic index in HE sections) in the control group of rats. 5-HT\textsubscript{7} receptor blockade had no effect on liver regeneration when applied 2h prior to partial hepatectomy. Liver regeneration was greatly attenuated when blockade of 5-HT\textsubscript{7} receptor was applied (by SB-258719 and SB-269970) at 16 h after partial hepatectomy and peaked at 32 h (\textsuperscript{[3]}H-thymidine incorporation into hepatic DNA and mitotic index by immunochemical detection of Ki67) and 40 h (mitotic index in HE sections) after partial hepatectomy. AS-19 administration totally reversed the observed attenuation of liver regeneration.

Conclusions: In conclusion, 5-HT\textsubscript{7} receptor is a novel type of serotonin receptor implicated in hepatocyte proliferation.

Keywords: Liver regeneration, Partial hepatectomy, 5-HT\textsubscript{7} receptor, SB-269970, SB-258719, AS-19

Background

Serotonin (5-HT) is an ancient chemical and neurotransmitter implicated in a vast variety of physiological and pathophysiological processes [1-3]. 5-HT mediates its actions through 14 distinct types of receptors encoded by a respective number of genes and its actions outnumber by far those of any other neurotransmitter. The majority of serotonin in the body (90\%) is synthesized in the GI tract by enterochromafin cells and is known to control mood, behavior, memory, sleep and anxiety in the central nervous system (CNS). In the periphery, serotonin mediates vascular contraction and relaxation, GI tract smooth muscle cell tone (contraction and/or relaxation), platelet aggregation and is also acting as a growth factor for diverse cell types promoting survival, cell differentiation and proliferation as well as inhibition of apoptosis [1-3].

In the liver, serotonin is implicated in the regulation of blood flow at the level of portal vein and sinusoids through activation of 5-HT\textsubscript{2} subtype of receptors [1], in biliary tree growth (5-HT\textsubscript{1\alpha} and 5-HT\textsubscript{1\beta} receptors), in the development of liver cirrhosis through activation and proliferation of HSC cells (5-HT\textsubscript{2\alpha} and 5-HT\textsubscript{2p}) and hepatocyte proliferation (mainly 5-HT\textsubscript{2\alpha/β}) [4]. Hepatocytes

© 2014 Tzirogiannis et al; licensee BioMed Central Ltd. This is an Open Access article distributed under the terms of the Creative Commons Attribution License (http://creativecommons.org/licenses/by/4.0), which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly credited. The Creative Commons Public Domain Dedication waiver (http://creativecommons.org/publicdomain/zero/1.0/) applies to the data made available in this article, unless otherwise stated.
express SERT, 5-HT2α and 5-HT2β and possibly other types of serotonin receptors and HSC cells express 5-HT1B, 5-HT1F, 5-HT2α, 5-HT2β, 5-HT7 and SERT [1].

Reports regarding implication of serotonin in liver regeneration are dated back in the early 80s in non-English literature or even earlier [5,6]. A number of recent in vivo studies including studies from our laboratory have elucidated the role of serotonin in liver regeneration after partial hepatectomy [7-9] with platelets to be the major reservoir accounting for the increased hepatic concentrations of the monoamine during liver regeneration. From experiments with 5-HT2 receptor blockade with ketanserin or ritanserin in our laboratory, it has become evident that serotonin exerts its actions mainly at the G1/S transition point and this suggests implication of the monoamine in the control of this major restrictive checkpoint of the cell cycle [8]. In cultured rat hepatocytes, in in vitro experiments, serotonin induces dose-dependent increase in DNA synthesis only in the presence of insulin and epidermal growth factor (EGF) [7] and recently serotonin has been shown to promote hepatocellular cancer growth in human hepatocellular cancer cell lines [10].

5-HT7 receptor has been the last family of serotonin receptors to be discovered. It is a Gs coupled receptor with at least four different splice variants that differ in the length of the C termini and in the number of phosphorylation sites, and the above have significant biochemical consequences in the G protein coupling efficiency and the differential susceptibility to desensitization [11]. The distribution of the receptor has not been fully elucidated and its mRNA is most abundant in the thalamus, hippocampus and hypothalamus. In the central nervous system, 5-HT7 receptor mediates thermoregulation, learning and memory, regulation of circadian rhythms and mood, and endocrine functions. In the periphery the receptor is localized mainly on smooth muscle cells in blood vessels in a variety of organs where it mediates relaxation of blood vessels as well as in the gastrointestinal tract where it regulates motility [2,3,12].

In the present study, we investigated the effect of 5-HT7 receptor blockade on liver regeneration after partial hepatectomy.

Methods
Experimental animal model
Male Wistar rats, weighing 160–200 g, four to five months old (Hellenic Pasteur Institute, Athens, Greece) were used in this study. The animals were kept in a temperature-controlled room (22-25°C), under 12 h of light (08.00 h-20.00 h) and 12 h of darkness (20.00 h-08.00 h) and they had free access to a commercial pellet diet and tap water. The study protocol was approved by the Deontology Committee of the University of Peloponese and animals were handled with humane care in accordance with the European Union Directive and adapted in the relevant Greek Presidential decree for the care and use of laboratory animals [13].

All surgical procedures were performed between 07.00-09.00 am with the animals under light ether anesthesia (di-ethyl ether per anesthesia; Codex, Carlo Erba, Milan, Italy). 5-HT7 receptor blockade was applied by intraperitoneal administration of SB-269970 hydrochloride (Sigma-Aldrich) and SB-258719 (Tokris Bioscience, Ellisville Missouri, USA). Reversion of 5-HT7 blockade was achieved by intraperitoneal administration of selective agonist AS-19 (Tokris Bioscience, Ellisville Missouri, USA).

The experimental rats were randomly assigned to the following groups:

Group A: rats submitted to 60-70% partial hepatectomy and intraperitoneal administration of normal saline 2 h prior and 16 h after partial hepatectomy.
Group B: rats submitted to 60-70% partial hepatectomy and intraperitoneal administration of SB-269970 hydrochloride at the dose of 2 mg/kg bodyweight 2 h prior to partial hepatectomy.
Group C: rats submitted to 60-70% partial hepatectomy and intraperitoneal administration of SB-269970 hydrochloride at the dose of 2 mg/kg bodyweight 16 h after partial hepatectomy.
Group D: rats submitted to 60-70% partial hepatectomy and intraperitoneal administration of SB-269970 hydrochloride at the dose of 2 mg/kg bodyweight 2 h prior and 16 h after partial hepatectomy.
Group E: rats submitted to 60-70% partial hepatectomy and intraperitoneal administration of SB-258719 at the dose of 4 mg/kg bodyweight 16 h after partial hepatectomy.
Group F: rats submitted to 60-70% partial hepatectomy, intraperitoneal administration of SB-269970 16 h after partial hepatectomy at the dose of 2 mg/kg bodyweight followed by intraperitoneal administration of AS-19 at the dose of 10 mg/kg bodyweight.
Group G: rats submitted to 60-70% partial hepatectomy, intraperitoneal administration of SB-258719 16 h after partial hepatectomy at the dose of 4 mg/kg bodyweight followed by intraperitoneal administration of AS-19 at the dose of 10 mg/kg bodyweight.

Dosage of SB-269970 and SB-258719 was determined after dose–response experiments (Figure 1). Pilot experiments were also conducted with AS-19 (administration at the doses of 1, 2, 5, 7.5 and 10 mg/kg) (Figure 2).

Animals from groups A, B and D were killed at 8, 18, 20, 24, 32, 40, 48, 60 and 72 h after partial hepatectomy via cardiac puncture. Animals of groups C, E, F, and G were sacrificed at 18, 20, 24, 32, 40, 48, 60 and 72 h after partial hepatectomy.
One hour prior to sacrifice the animals of all groups were injected with [3H]-thymidine at the dose of 250 μCi/kg bodyweight intraperitoneally. A standard portion of the median liver lobe was used for histological evaluation and the rest was rapidly frozen in liquid nitrogen for further determinations. Liver weights were also tabulated for all groups of rats.

**Histological evaluation**

A standard portion of the median liver lobe was fixed in 4% buffered formalin for 24 hours. Sections 5-μm thick were processed routinely, stained with hematoxylin-eosin (HE) and analysed for mitoses. Mitoses were counted in 10 randomly selected high-power fields (HPF) and expressed as the mean number of mitoses/HPF. The mitotic index was also evaluated by the immunochemical detection of Ki67 nuclear antigen (Dako, MIB 5 clone, 1:50, with microwave pre-treatment).

**Liver regeneration**

The rate of liver regeneration was evaluated by the rate of [3H]-thymidine incorporation into hepatic DNA, the mitotic index in HE sections and by immunochemical detection of Ki67 nuclear antigen.

**Rate of [3H]-thymidine Incorporation into Hepatic DNA**

Animals of all groups were injected intraperitoneally with 250 μCi/kg bodyweight of [3H]-thymidine 1 h prior to sacrifice. DNA was extracted from the tissue according to the method of Munro and Fleck [14] as modified by Kyprianidis et al. [15]. The content of tissue DNA was estimated by the method of Richards [16]. The rate of [3H]-thymidine incorporation into hepatic DNA was calculated from the radioactivity measured in a liquid scintillation counter (Wallac LKB 1211 Rackbeta, Sweden) and results were expressed as counts/min/μg of DNA.

**Analysis of liver and serum lipid content**

Frozen liver tissue (~100 mg) was homogenised in 1.6 ml phosphate-buffered saline and protein concentration was determined using the method of Lowry [17]. Lipids were extracted using chloroform: methanol (2:1) according to Folch et al. [18]. Phase separation was achieved with sulphuric acid 0.1% and the organic phase was solubilized in Triton X-100. Cholesterol, TG, FFA and phospholipid content were determined in liver tissue and plasma with the use of commercially available kits (Wako, Chemicals) and normalized to protein concentration of the homogenate. Free plasma glycerol levels were also determined in deproteinised serum samples as an indicator of lipolysis in adipose tissue [19].

**Statistical analysis**

Data were expressed as means ± SE. All observations were obtained from at least five animals. The statistical analysis of the results was performed by unpaired Student’s t-test.

**Results**

In rats subjected to 60-70% partial hepatectomy (group A), liver regeneration as evaluated by [3H]-thymidine incorporation into hepatic DNA, peaked at 24 and 32 h after partial hepatectomy and high rates were also observed at 40 h. The regenerative rates declined abruptly after 40 h and remained at low levels thereafter (Figure 3).
In rats subjected to 60-70% partial hepatectomy and intraperitoneal administration of SB-269970 2 h prior to partial hepatectomy (group B), [3H]-thymidine incorporation into hepatic DNA was maximal at 24 h and 32 h after partial hepatectomy with high rates also at 40 h (Figure 3). The temporal pattern and values of regenerative rate were almost identical in groups A and B of rats (Figure 3).

In group C of rats, intraperitoneal administration of SB-269970 16 h after partial hepatectomy greatly attenuated liver regeneration as evaluated by [3H]-thymidine incorporation into hepatic DNA at 24 h after partial hepatectomy (Figure 3). [3H]-thymidine incorporation into hepatic DNA was maximal at 32 h after partial hepatectomy in group C of rats and sharply declined thereafter (Figure 3). The maximal regenerative rate observed at 32 h in group C as well as the regenerative rates at all time points examined in this group were lower than the corresponding rates at the same time points for groups A and B (Figure 3).

In group D of rats, [3H]-thymidine incorporation into hepatic DNA peaked at 32 h after partial hepatectomy showing the same temporal pattern as in group C (Figure 3). As in group C, liver regeneration was greatly attenuated at all time points examined.

In group E of rats, [3H]-thymidine incorporation into hepatic DNA peaked at 32 h after partial hepatectomy showing the same temporal pattern and similar values as in groups C and D (Figure 4). As in group C, liver regeneration was greatly attenuated at all time points examined.

In groups F and G, AS-19 administration reversed the observed attenuation of liver regeneration and [3H]-thymidine incorporation into hepatic DNA peaked at 24 and 32 h after partial hepatectomy while it was also at high levels at 40 h. The time pattern and values of [3H]-thymidine incorporation into hepatic DNA in groups F and G were almost identical with that in group A (Figures 5 and 6).
Mitotic index in HE sections was maximal at 32 h after partial hepatectomy in groups A and B with also relatively high levels at 24, 40 and 48 h and sharply declined thereafter (Figure 7). In groups C and D of rats, mitotic index was minimal until 32 h and two major peaks were observed at 40 and 60 h that were both lower than the corresponding peaks in groups A and B at 32 h (Figure 7).

Mitotic index as evaluated by the immunochemical detection of Ki67 gradually increased between 8 and 24 h when it peaked in groups A and B of rats and remained at high levels until 40 h with abrupt decline thereafter (Figures 8 and 9). The index remained at low levels between 8 and 24 h after partial hepatectomy in groups C and D of rats with sharp increase at 32 h (Figures 8 and 10). The percentage of Ki67 nuclei remained at relatively high levels until 48 h after partial hepatectomy with gradual decrease afterwards in these groups of rats (Figure 8). The regenerative rate as evaluated by Ki67 positive cells in groups C and D at 32 and 40 h was lower than that in groups A and B.

In group F intraperitoneal administration of AS-19 at the dose of 10 mg/kg of body weight totally reversed the observed attenuation of liver regeneration as evaluated by the percentage of Ki67 positive cells and regenerative rates were almost identical with these in group A (Figure 11). The observed effect of AS-19, as evaluated in initial pilot experiments was dose-dependent (Figure 2). In group G of rats AS-19 administration also totally reversed the observed inhibition of liver regeneration and the time pattern...
and values of Ki67 positive cells were also almost identical with these in groups A and F (data not shown).

Relative liver weight (liver weight in g/100 g bodyweight) sharply decreased, as expected after partial hepatectomy, with gradual increase thereafter in group A of rats. In groups C, D and E, relative liver weight remained at low levels without significant increases until 24 h after partial hepatectomy. In these groups a small increase was observed at 32 h with further increase at 40 and 48 h after partial hepatectomy. In groups F and G of rats, the relative liver weights showed the same gradual increases as in group A (Table 1).

Regarding lipid changes after partial hepatectomy, increase in liver triglyceride levels was observed at 18 h after partial hepatectomy with further increase at 24 h in group A of rats. Liver triglyceride content peaked at 40 h after partial hepatectomy and decreased thereafter but was still at high levels at 72 h after partial hepatectomy. Serum triglyceride concentration decreased at 18 and 24 h after partial hepatectomy and increased afterwards and these increases were still present at 72 h after partial hepatectomy. Serum FFA and free glycerol levels both increased at 18 h after partial hepatectomy and remained at high levels thereafter. The temporal patterns of liver and plasma lipid changes were similar in all groups of rats (Tables 2 and 3).

Discussion

The ability of the liver to regenerate after surgical resection or any short of hepatic injury has been known from long and has drawn immense scientific interest. 60-70% partial hepatectomy is the most commonly applied stimulus for the study of liver regeneration mainly due to the fact that the mitotic stimulus is accurately applied in time and not associated with necrotic or inflammatory processes [20]. A great number of substances influence the regenerative process and traditionally they are classified as complete and incomplete (auxiliary) mitogens [20].

The autonomic nervous system, both sympathetic and parasympathetic, is implicated in liver regeneration although the exact mechanisms of its effects still remain obscure [21-23]. Among neurotransmitters norepinephrine, mainly through α1-adrenergic receptor [23-25] (actions through β-adrenergic receptors have also been reported [26], and serotonin, mainly through 5-HT2 receptor, are considered auxiliary mitogens [7-9].
Serotonin is an important neurotransmitter of the autonomic nervous system and in the liver serotonergic nerve fibres are localized in the tunica media of branches of the hepatic artery, portal vein, bile ducts and the connective tissue of the interlobular septae in humans and rats [27,28]. 5-HT receptors are expressed in various liver cell types, apart from hepatocytes, as hepatic stellate cells and sinusoidal endothelial cells [4,29,30].

From experiments on differential 5-HT receptor subtype expression and blockade experiments with various receptor antagonists of other research groups it has become evident that 5-HT$_2$$\alpha$ and 5-HT$_3$$\beta$ receptors mediate liver regeneration [31] and molecular pathways have been elucidated in the case of 5-HT$_2$$\alpha$ receptor [32-34].

In our study, 5-HT$_7$ receptor blockade greatly attenuated liver regeneration when applied close to the G$_{1}$S transition point of the cell cycle and this is the first study to reveal implication of the 5-HT$_7$ receptor in liver regeneration and more specifically in this major restrictive cell cycle check point. In the central nervous system, blockade of 5-HT$_7$ receptor has been reported to increase hippocampal cell proliferation [35] and the receptor is also implicated at least in the initial stages of T-cell activation and possibly in T-cell proliferation [36]. Additionally, 5-HT$_7$ receptor has been recently found to be expressed in hepatocytes although the full repertoire of its actions in the liver still remains obscure [37].

SB-269970 used in our study is considered a highly selective ligand for 5-HT$_7$ receptors (pKi= 8.9 ± 0.1) with at least 100-fold greater affinity in relation to other types of 5-HT receptor subtypes but some researchers have also reported that it is also a potent $\alpha_2$-adrenergic receptor blocker [38-41]. Although only $\alpha_2$-adrenoreceptors have been reported to participate in liver regeneration, the observed inhibitory effect by SB-269970 could also be attributed to $\alpha_2$-receptor blockade especially since $\alpha_2$-adrenoreceptors are expressed in hepatocytes [42,43]. Activation of $\alpha_2$-adrenergic receptors has been reported to induce cell proliferation in different cell types [44-46], whereas competitive inhibition of these receptors attenuates cell proliferation and/or induces apoptosis [44,45,47]. However, there are reports that connect $\alpha_2$-receptor stimulation with inhibition of cell growth [48]. In order to elucidate the above, another series of experiments has been conducted in our laboratory with intraperitoneal administration of SB-258719 (pKi= 7.5) at the dose of 4 mg/kg bodyweight at 16 h after partial hepatectomy [38,49,50]. SB-258719 is a known weak inverse agonist of 5-HT$_7$ receptor without any known actions on other type of serotonin receptors and its administration had the same effect on liver regeneration as SB-269970 administration and the above clearly suggests that the observed inhibitory effect must be attributed to 5-HT$_7$ receptor blockade.

In order to verify that the observed effect on liver regeneration is due to blockade of 5-HT$_7$ receptor we conducted another series of experiments with the selective 5-HT$_7$ receptor agonist AS-19 [51-53]. AS-19 is considered a selective 5-HT$_7$ agonist (K$_i$= 0.6 nM, IC$_{50}$ = 0.83nM) [54]. AS-19 administration reversed the observed attenuation of liver regeneration caused by administration of SB-269970 and SB-258719 and this verifies the implication of 5-HT$_7$ in liver regeneration.

It is known from long that liver regeneration is accompanied by transient hepatic steatosis and intracellular accumulation of triglycerides in hepatocytes through increased lipolysis in the adipose tissue and increased hepatic lipogenesis [55,56]. Serotonin induces lipolysis in adipocytes and promotes gluconeogenesis in hepatocytes through 5-HT$_2$$\beta$ receptor during fasting adaptation [57]. Additionally serotonin is also implicated in the regulation of lipid metabolism through 5-HT$_2$$\alpha$ receptors by altering sympathetic outflow at the brain level [58]. In our experiments no significant differences have been observed in serum and liver lipids during liver regeneration after 5-HT$_3$ receptor blockade and consequently 5-HT$_7$ receptor does not seem to be implicated in the adaptive changes of lipid metabolism during liver regeneration.

| Hours after partial hepatectomy | Relative liver weights (g/100 g body weight) |
|-------------------------------|------------------------------------------|
|                               | Group A | Group C | Group E | Group F | Group G |
| 8                             | 1.6 ± 0.1 | 1.5 ± 0.1 | 1.6 ± 0.1 | 1.7 ± 0.2 | 1.6 ± 0.1 |
| 18                            | 1.9 ± 0.2 | 1.7 ± 0.1 | 1.6 ± 0.1 | 2.0 ± 0.2 | 2.0 ± 0.1 |
| 24                            | 2.3 ± 0.2 | 1.7 ± 0.1 | 1.8 ± 0.1 | 2.2 ± 0.2 | 2.4 ± 0.2 |
| 32                            | 2.6 ± 0.3 | 2.3 ± 0.2 | 2.2 ± 0.2 | 2.5 ± 0.3 | 2.7 ± 0.2 |
| 40                            | 3.1 ± 0.3 | 2.6 ± 0.2 | 2.6 ± 0.1 | 3.1 ± 0.2 | 3.0 ± 0.3 |
| 48                            | 3.5 ± 0.2 | 2.7 ± 0.2 | 2.8 ± 0.2 | 3.4 ± 0.3 | 3.4 ± 0.3 |
| 60                            | 3.7 ± 0.2 | 2.7 ± 0.2 | 2.7 ± 0.1 | 3.8 ± 0.2 | 3.7 ± 0.3 |
| 72                            | 4.2 ± 0.2 | 2.6 ± 0.1 | 2.8 ± 0.1 | 4.1 ± 0.3 | 4.3 ± 0.2 |

The mean relative liver weight for normal rats (n = 5) of the same age and weight range was 4.5 ± 0.3.
| Time after PH (hours) | Group ALiver triacylglycerol (μg/mg of protein) | Serum triacylglycerol (mg/dl) | Serum glycerol (μmol/l) | Serum FFA (μmol/ml or mmol/l) | Group CLiver triacylglycerol (μg/mg of protein) | Serum triacylglycerol (mg/dl) | Serum glycerol (μmol/l) | Serum FFA (μmol/ml or mmol/l) | Group DLiver triacylglycerol (μg/mg of protein) | Serum triacylglycerol (mg/dl) | Serum glycerol (μmol/l) | Serum FFA (μmol/ml or mmol/l) |
|----------------------|-----------------------------------------------|-------------------------------|------------------------|-------------------------------|-----------------------------------------------|-------------------------------|------------------------|-------------------------------|-----------------------------------------------|-------------------------------|------------------------|-------------------------------|
| 0                    | 15.8 ± 0.8                                    | 6.2 ± 0.6                     | 61.2 ± 5.2             | 0.32 ± 0.05                   | 15.8 ± 0.8                                    | 6.2 ± 0.6                     | 61.2 ± 5.2             | 0.32 ± 0.05                   | 15.8 ± 0.8                                    | 6.2 ± 0.6                     | 61.2 ± 5.2             | 0.32 ± 0.05                   |
| 8                    | 16.8 ± 0.9                                    | 5.8 ± 0.6                     | 75.4 ± 6.5             | 0.44 ± 0.05                   | N.D.                                          | N.D.                          | N.D.                   | N.D.                          | 17.4 ± 1.3                                    | 6.0 ± 0.9                     | 72.8 ± 6.1             | 0.50 ± 0.06                   |
| 18                   | 28.1 ± 2.3                                    | 3.8 ± 0.4                     | 188.6 ± 8.8            | 0.86 ± 0.07                   | 27.5 ± 3.1                                    | 4.2 ± 0.4                     | 174.2 ± 7.5            | 0.82 ± 0.08                   | 29.4 ± 2.4                                    | 3.5 ± 0.6                     | 179.4 ± 7.8            | 0.89 ± 0.08                   |
| 20                   | 30.6 ± 3.4                                    | 3.6 ± 0.5                     | 192.2 ± 9.5            | 0.84 ± 0.08                   | 29.7 ± 2.5                                    | 3.9 ± 0.4                     | 100.3 ± 6.1            | 0.86 ± 0.09                   | 31.2 ± 2.6                                    | 3.3 ± 0.4                     | 195.1 ± 8.2            | 0.81 ± 0.06                   |
| 24                   | 34.8 ± 3.8                                    | 3.4 ± 0.4                     | 187.8 ± 9.1            | 0.82 ± 0.07                   | 35.3 ± 3.4                                    | 3.2 ± 0.5                     | 195.2 ± 8.9            | 0.89 ± 0.09                   | 36.2 ± 2.9                                    | 3.0 ± 0.4                     | 189.3 ± 8.8            | 0.79 ± 0.07                   |
| 32                   | 37.2 ± 2.3                                    | 5.6 ± 0.6                     | 204.2 ± 10.4           | 0.90 ± 0.06                   | 38.1 ± 3.8                                    | 4.8 ± 0.4                     | 197.5 ± 9.3            | 0.94 ± 0.08                   | 37.8 ± 2.7                                    | 5.4 ± 0.7                     | 201.8 ± 9.4            | 0.88 ± 0.09                   |
| 40                   | 40.1 ± 3.4                                    | 6.4 ± 0.7                     | 196.3 ± 10.1           | 0.86 ± 0.09                   | 41.3 ± 4.2                                    | 5.9 ± 0.6                     | 203.4 ± 8.7            | 0.88 ± 0.07                   | 39.2 ± 3.1                                    | 6.7 ± 0.8                     | 204.9 ± 8.5            | 0.91 ± 0.09                   |
| 48                   | 33.8 ± 2.6                                    | 7.4 ± 0.7                     | 205.1 ± 9.5            | 0.84 ± 0.08                   | 34.5 ± 3.5                                    | 7.1 ± 0.7                     | 197.8 ± 9.5            | 0.84 ± 0.09                   | 31.6 ± 2.5                                    | 7.8 ± 0.9                     | 209.5 ± 9.7            | 0.80 ± 0.08                   |
| 60                   | 26.6 ± 2.2                                    | 7.2 ± 0.8                     | 179.9 ± 8.6            | 0.83 ± 0.07                   | 27.6 ± 3.1                                    | 7.4 ± 0.6                     | 189.7 ± 7.8            | 0.81 ± 0.08                   | 27.3 ± 1.9                                    | 7.7 ± 0.6                     | 192.5 ± 8.3            | 0.78 ± 0.08                   |
| 72                   | 24.6 ± 1.6                                    | 7.0 ± 0.6                     | 204.1 ± 8.9            | 0.85 ± 0.08                   | 26.5 ± 2.6                                    | 7.5 ± 0.7                     | 196.8 ± 7.5            | 0.80 ± 0.07                   | 23.2 ± 1.7                                    | 7.2 ± 0.8                     | 189.6 ± 7.8            | 0.74 ± 0.06                   |

Values are expressed as mean ± standard error.
FFA = Free fatty acid.
N.D. = Not Determined.
Table 3 Liver and serum triacylglycerol levels and serum glycerol and FFA levels in groups E, F and G

| Time after PH (hours) | Group E | | | Group F | | | Group G | | |
|-----------------------|---------|---------|---------|---------|---------|---------|---------|---------|---------|
|                       | Liver triacylglycerol (µg/mg of protein) | Serum triacylglycerol (mg/dl) | Serum glycerol (µmol/l) | Serum FFA (µmol/ml or mmol/l) | Liver triacylglycerol (µg/mg of protein) | Serum triacylglycerol (mg/dl) | Serum glycerol (µmol/l) | Serum FFA (µmol/ml or mmol/l) | Liver triacylglycerol (µg/mg of protein) | Serum triacylglycerol (mg/dl) | Serum glycerol (µmol/l) | Serum FFA (µmol/ml or mmol/l) |
| 0                     | 15.8 ± 0.8 | 6.2 ± 0.6 | 61.2 ± 5.2 | 0.32 ± 0.05 | 15.8 ± 0.8 | 6.2 ± 0.6 | 61.2 ± 5.2 | 0.32 ± 0.05 | 15.8 ± 0.8 | 6.2 ± 0.6 | 61.2 ± 5.2 | 0.32 ± 0.05 |
| 18                    | 30.3 ± 2.9 | 4.0 ± 0.6 | 180.7 ± 8.3 | 0.85 ± 0.09 | 28.9 ± 3.3 | 3.8 ± 0.5 | 175.9 ± 8.5 | 0.72 ± 0.08 | 29.9 ± 3.8 | 4.2 ± 0.8 | 184.8 ± 8.8 | 0.81 ± 0.08 |
| 20                    | 32.7 ± 3.8 | 3.7 ± 0.5 | 191.3 ± 8.9 | 0.83 ± 0.06 | 30.8 ± 3.5 | 3.9 ± 0.5 | 190.7 ± 9.0 | 0.79 ± 0.09 | 34.3 ± 3.1 | 3.6 ± 0.7 | 196.7 ± 8.5 | 0.77 ± 0.08 |
| 24                    | 35.7 ± 3.9 | 3.5 ± 0.5 | 194.5 ± 9.7 | 0.80 ± 0.07 | 34.4 ± 3.8 | 3.4 ± 0.7 | 193.8 ± 8.5 | 0.87 ± 0.13 | 37.2 ± 3.5 | 3.1 ± 0.6 | 195.2 ± 9.2 | 0.79 ± 0.07 |
| 32                    | 39.5 ± 3.3 | 5.0 ± 0.9 | 201.6 ± 10.3 | 0.93 ± 0.11 | 42.3 ± 4.0 | 5.3 ± 0.9 | 198.5 ± 9.9 | 0.96 ± 0.15 | 38.8 ± 3.7 | 4.5 ± 0.9 | 207.8 ± 10.4 | 0.90 ± 0.09 |
| 40                    | 42.6 ± 4.1 | 6.7 ± 0.6 | 199.2 ± 10.8 | 0.86 ± 0.09 | 446.4 ± 4.6 | 6.3 ± 1.1 | 205.6 ± 10.7 | 0.91 ± 0.09 | 43.4 ± 3.6 | 6.1 ± 0.9 | 210.9 ± 9.5 | 0.95 ± 0.09 |
| 48                    | 35.9 ± 2.9 | 7.7 ± 0.8 | 206.7 ± 11.3 | 0.83 ± 0.08 | 37.5 ± 3.9 | 7.6 ± 0.9 | 203.7 ± 10.2 | 0.87 ± 0.08 | 32.9 ± 3.5 | 7.2 ± 1.2 | 203.7 ± 10.7 | 0.81 ± 0.08 |
| 60                    | 27.4 ± 2.6 | 7.1 ± 0.9 | 182.9 ± 9.6 | 0.81 ± 0.08 | 29.8 ± 3.3 | 7.4 ± 0.9 | 185.8 ± 8.8 | 0.82 ± 0.07 | 26.3 ± 2.4 | 7.3 ± 0.9 | 172.7 ± 8.9 | 0.73 ± 0.07 |
| 72                    | 23.6 ± 2.2 | 6.7 ± 0.6 | 200.4 ± 9.9 | 0.85 ± 0.09 | 25.6 ± 2.9 | 6.5 ± 0.8 | 203.6 ± 9.5 | 0.76 ± 0.09 | 21.8 ± 1.9 | 7.0 ± 1.0 | 192.6 ± 7.5 | 0.81 ± 0.09 |

Values are expressed as mean ± standard error.

FFA = Free fatty acid.
5-HT₂ receptors have been reported to activate MAPK [59,60] and this activation has also been reported to be RAS-dependent [61]. The above seems to represent a more general pattern of MAPK activation from Gs-coupled receptors with RAS independent pathways to have also been described [62,63]. Both 5-HT₁A and 5-HT₂ receptors have also been reported to activate MAPK through similar pathways [33,64] and this hints at a possible role of 5-HT₁ receptor in mitogenesis and cell-cycle progression although further research is needed at this point.

Conclusions

The results of this study indicate that 5-HT₂ receptor is implicated in liver regeneration after partial hepatectomy. Serotonin through 5-HT₂ receptor seems to exert its auxillary proliferative effect close to G1/S transition point and during the S phase. Therefore, the results identify a novel type of 5-HT receptor that mediates the proliferative effect of the monoamine in the liver.

Abbreviations

5-HT: Serotonin; HE: Hematoxylin-eosin; CNS: Central nervous system; GI: Gastro-intestinal; EGF: Epidermal growth factor; HPP: High-power fields; MAPK: Mitogen-activated protein kinase.

Competing interests

The authors declare that they have no competing interests.

Authors’ contributions

KNT and GJP designed the study; KNT, KTK, SZ, and GJP coordinated the study; KNT, KTK, ADG, MT, SZ, DP, IP, VP and GJP performed the study; KNT, KTK, MT, SZ, DP, VP, IP and GJP analyzed the data; KTK, MT, SZ, VP helped to draft the manuscript; and KNT and GJP wrote the manuscript. All authors read and approved the final manuscript.

Author details

1Department of Experimental Pharmacology, Medical School, Athens University, Athens 11527, Greece. 2Department of Nursing, Faculty of Human Movement and Quality of Life Sciences, University of Peloponnese, Sparta 23100, Greece. 3Department of Internal Medicine, Tzania General Hospital of Piraeus, Piraeus 18537, Greece. 4Department of Nursing, Faculty of Human Movement and Quality of Life Sciences, University of Peloponnese, Orthias Artemidores and Plateon, Sparta 23100, Greece.

Received: 28 February 2014 Accepted: 11 November 2014

Published online: 30 November 2014

References

1. Ruddell RG, Mann DA, Ramm GA: The function of serotonin within the liver. J Hepatol 2008, 48:666–675.
2. Beattie DT, Smith JA: Serotonin Pharmacology in the gastrointestinal tract: a review. Naunyn Schmiedebergs Arch Pharmacol 2008, 377:181–203.
3. Lesurtel M, Soll C, Graf R, Clavien PA: Role of serotonin in the hepatogastrintestinal tract: an old molecule for new perspectives. Cell Mol Life Sci 2008, 65:940–952.
4. Ruddell RG, Oakley F, Hussain Z, Yeung I, Bryan-Lluka LJ, Ramm GA, Mann DA: A Role for serotonin (5-HT) in hepatic Steatate Cell Function and Liver Fibrosis. Am J Pathol 2006, 169:861–876.
5. Kulinski VI, Saratatkov AS, Vstavskiaia IA, Udovtisina TI: Receptors mediating serotonin-stimulating liver regeneration in mice. Bull Exp Biol Med 1983, 95:89–91.
6. Kulinski VI, Udovtisina TI, Vstavskiaia IA, Rykov SA: Comparison of the changes in mitotic activity and in serotonin concentration in regenerating liver. Vopr Med Khim 1983, 29:104–107.
7. Balasubramanian S, Paulose CS: Induction of DNA synthesis in primary cultures of rat hepatocytes by serotonin: possible involvement of serotonin 52 receptor. Hepatology 1998, 27:62–66.
8. Papadimas GK, Tzirogiannis KN, Panoutsopoulou GI, Demokanou MD, Skaltas SD, Hereti RI, Papadopoulou-Dafizoti Y, Mykoniotis MG: Effect of serotonin receptor 2 blockade on liver regeneration after partial hepatectomy in the rat liver. Liver Int 2006, 28:352–361.
9. Lesurtel M, Graf R, Aleli B, Walther DJ, Tian Y, Jochum W, Gachet C, Bader M, Clavien PA: Platelet-derived serotonin mediates liver regeneration. Science 2006, 312:104–107.
10. Soll C, Jang JH, Riener MO, Moritz W, Wild PJ, Graf R, Clavien PA: Serotonin promotes tumor growth in Human Hepatocellular Cancer. Hepatology 2010, 51:1244–1254.
11. Vanhoeckner P, Haegeeman G, Leyens JE: 5-HT receptors: current knowledge and future prospects. Trends Pharmacol Sci 2000, 21:70–77.
12. Hedlund PB, Sutcliffe JS: Functional, molecular and pharmacological advances in 5-HT 7 receptor research. Trends Pharmacol Sci 2004, 25:481–486.
13. GREEK PRESIDENTIAL DECREE No 160/1991: Protection of Animals Used for Experimental and Other Scientific Purposes in Accordance With EU Directive 86/609/EEC of the Council, Governmental Gazette No 64, 1991.
14. Munro HN, Fleck A: Recent developments in the measurement of nucleic acids in biological materials. Analyst 1966, 91:78–88.
15. Kyriandis KG, Mykoniotis MG, Papadimitriou DG, Valsamidou A: Effect of subtotal pancreatectomy on the rate of liver regeneration: the role of hepatic stimulator substance. J Surg Res 1996, 62:267–272.
16. Richards G: Modifications of the diphenylamine reaction giving increased sensitivity and simplicity in the estimation of DNA. Anal Biochem 1974, 57:369–376.
17. Lowey G, Rosenbrough N, Farr A, Randall R: Protein measurement with the folin phenol reagent. J Biol Chem 1951, 193:265–275.
18. Folch J, Lees M, Sloane Stanley GH: A simple method for the isolation and purification of total lipids from animal tissues. J Biol Chem 1982, 28:997–309.
19. Tijburg LB, Marpediano A, Biljeld C, Guzman M, Geelen MJ: Effects of ethanol feeding on hepatic lipid synthesis. Arch Biochem Biophys 1988, 267:568–579.
20. Michalopoulos GK: Liver regeneration after partial Hepatectomy: critical analysis of mechanistic dilemmas. Am J Pathol 2010, 1762–13.
21. Tanaka K, Okhawa S, Nishino T, Nijima A, Inoue S: Role of the hepatic branch of the vagus nerve in liver regeneration in rats. Am J Physiol 1997, 253:G439–G444.
22. Oben JA, Diehl AM: Sympathetic nervous system regulation of liver repair. Anat Rec A: Discov Mol Cell Biol Evol Bio 2004, 280:874–883.
23. Cruize JL, Knecht SJ, Bollinger RR, Kuhn C, Michalopoulos G: Alpha 1-adrenergic effects and liver regeneration. Hepatology 1987, 7:1189–1194.
24. Cruize JL, Houck KA, Michalopoulos G: Early events in the regulation of Hepatocyte DNA synthesis: the role of alpha- adrenergic stimulation. Scand J Gastroenterol 1988, 151:19–30.
25. Cruize JL, Houck KA, Michalopoulos G: Induction of DNA synthesis in cultured rat hepatocytes through stimulation of alpha 1 adrenoceptor by norepinephrine. Science 1985, 227:749–751.
26. Refnes M, Thoresen GH, Sandnes D, Dajani OF, Dajani L, Christoffersen T: Stimulatory and inhibitory effects of catecholamines on DNA synthesis in primary rat hepatocyte cultures: role of alpha1- and beta-adrenergic mechanisms. J Cell Physiol 1992, 151:164–171.
27. El-Salhy M, Sterling R, Grimmelius L: Peptidergic innervation and endocrine cells in the human liver. Scand J Gastroenterol 1993, 28:809–815.
28. Svanova JL: Relevance of mast cells and hepatic lobule innervations to liver. Rom J Gastroenterol 2004, 13:203–209.
29. Braunies U, Gattinanion Z, Arias AM: Serotonin stimulates a Ca²⁺ permeant nonspecific cation channel in hepatic endothelial cells. Biochem Biophys Res Commun 1992, 186:1560–1566.
30. Gatmanian Z, Varticovski L, Ling L, Mikkelson R, Steffan AM, Arias IM: Studies on fenestral contraction in rat liver endothelial cells in culture. Am J Pathol 1996, 148:2027–2041.
31. Clavien PA: Liver regeneration: a spotlight on the novel role of platelets and serotonin. Swiss Med Wkly 2008, 138:361–370.
32. Gooz M, Gooz P, Luttrell LM, Raymond JR: S-HT2A receptor induces ERK phosphorylation and proliferation through ADAM-17 tumor necrosis factor-alpha-converting enzyme (TACE) activation and heparin-bound epidermal growth factor-like growth factor (HB-EGF) shedding in mesangial cells. J Biol Chem 2006, 281:21004–21012.

33. Nebigil CG, Launay JM, Hickel P, Toumais-C, Maroteaux L: 5-hydroxytryptamine 2B receptor regulates cell-cycle progression: cross-talk with tyrosine kinase pathways. Proc Natl Acad Sci USA 2000, 97:2591–2596.

34. Liu Y, Li M, Warburton RR, Hill NS, Fanbug BL: The S-HT transporter transactivates the PDGF beta receptor in pulmonary artery smooth muscle cells. FASEB J 2007, 21:2725–2734.

35. Mnie-Filali O, Faure C, Lambas-Senaz L, El Mansari M, Belbidia G, Gondard E, Eteviant A, Scama H, Didier A, Berod A, Blier P, Haddjeri N: Pharmacological blockade of S-HT7 receptors as a putative fast acting antidepressant strategy. Neuropsychopharmacology 2011, 36:1275–1288.

36. Leon-Ponte M, Ahern GP, O’Connell PJ: Serotonin provides an accessory signal to enhance T-cell activation by signaling through the S-HT7 receptor. Blood 2007, 109:3139–3146.

37. Svejda B, Kidd M, Timberlake A, Harry K, Kazberouk A, Schimmack S, Lawrence B, Fugger R, Modlin ML: Serotonin and the S-HT7 receptor: the link between hepatocytes, IFG-1 and small intestinal neuroendocrine tumors. Cancer Sci 2010, 101:844–855.

38. Mahe C, Loetscher P, Feuerbach D, Muller W, Seiler MP, Schoeffter P: Characterization of SB-269970-A, a selective 5-HT(7) receptor antagonist. Br J Pharmacol 2005, 145:211–222.

39. Lovell PJ, Bromidge SM, Dabbs S, Duckworth DM, Forbes IT, Jennings AJ, King FD, Middlemiss DN, Rahman SK, Saunders DV, Collin LL, Hagan JJ, Riley GJ, Thomas DR: A novel, potent, and selective S-HT7 antagonist: (R)-3, N-dimethyl-N-[1-methyl-3-(4-methyl-piperidin-1-yl)propyl]benzenesulfonamide: the first selective 5-HT7 antagonist. J Med Chem 1998, 41:5655–5670.

40. Brenchat A, Rocasalbas M, Zamanillo D, Hamon M, Vela J, Romero L: Assessment of S-HT7 receptor agonists selectivity using nociceptive and thermoregulation tests in knockout versus wild-type mice. Adv Pharmacol Soc 2012, 2012:312041.

41. Tijburg LB, Nyathi CB, Meijer GW, Geelen MJ: Biosynthesis and secretion of triacylglycerol in rat liver after partial hepatectomy. Biochem J 1991, 277:725–728.

42. Rudnick DA: Trimming the fat from liver regeneration. Hepatology 2005, 42:1001–1003.

43. Sumara G, Sumara O, Kim JK, Karsenty G: Gut-derived serotonin is a multifunctional determinant to fasting adaptation. Cell Metab 2012, 16:588–600.

44. Nonogaki K: New insights into sympathetic regulation of glucose and fat metabolism. Diabetologia 2000, 43:533–549.

45. Watts SW, Yang P, Banes AK, Rasz E: Activation of Erk mitogen-activated protein kinase proteins by vascular serotonin receptors. J Cardiovasc Pharmacol 2001, 38:539–551.

46. Lieb K, Biersack L, Waschbiisch A, Orlikowski S, Akundi ES, Candelario-Jalil E, Hull M, Fiebich BL: Serotonin via S-HT7 receptors activates p38 mitogen-activated protein kinase and protein kinase C epsilon resulting in interleukin-6 synthesis in human U373 MG astrocytoma cells. J Neurochem 2005, 93:549–559.

47. Norum JH, Hart K, Levy FQ: Ras-dependent ERK activation by the human G(i)-coupled serotonin receptors S-HT4(b) and S-HT7(a). J Biol Chem 2003, 278:3098–3104.

48. Klinger M, Kudlacek O, Seidel MG, Freismuth M, Sexl V: MAP kinase stimulation by cAMP does not require RAP1 but SRC family kinases. J Biol Chem 2002, 277:32490–32497.

49. Erensen JK, Christensen AE, de Rooij J, van Triest M, Schwede F, Genieser HG, Dokseland JL, Blank J, Bos JL: A novel Epac-specific cAMP analogue demonstrates independent regulation of Rap1 and ERK. Nat Cell Biol 2002, 4:901–906.

50. Banes A, Florian JA, Watts SW: Mechanisms of S-Hydroxytryptamine (2A) receptor activation of the mitogen-activated protein kinase pathway in vascular smooth muscle. J Pharmacol Exp Ther 1999, 291:1179–1187.

Cite this article as: Tzirogiannis et al. Effect of S-HT7 receptor blockade on liver regeneration after 60-70% partial hepatectomy. BMC Gastroenterology 2014, 14:201.